EA201892045A1 - ПРОИЗВОДНЫЕ α-ТРУКСИЛЛОВОЙ КИСЛОТЫ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ С НИМИ - Google Patents

ПРОИЗВОДНЫЕ α-ТРУКСИЛЛОВОЙ КИСЛОТЫ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ С НИМИ

Info

Publication number
EA201892045A1
EA201892045A1 EA201892045A EA201892045A EA201892045A1 EA 201892045 A1 EA201892045 A1 EA 201892045A1 EA 201892045 A EA201892045 A EA 201892045A EA 201892045 A EA201892045 A EA 201892045A EA 201892045 A1 EA201892045 A1 EA 201892045A1
Authority
EA
Eurasian Patent Office
Prior art keywords
derivatives
pharmaceutical compositions
truxillic acid
truxillic
acid
Prior art date
Application number
EA201892045A
Other languages
English (en)
Inventor
Ивао Одзима
Дейл Дойч
Мартин Качоха
Кунчжэнь Ху
Саймон Тун
Мэтью Элмес
Су Янь
Original Assignee
Те Рисерч Фаундейшн Фор Те Стейт Юниверсити Оф Нью Йорк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Те Рисерч Фаундейшн Фор Те Стейт Юниверсити Оф Нью Йорк filed Critical Те Рисерч Фаундейшн Фор Те Стейт Юниверсити Оф Нью Йорк
Publication of EA201892045A1 publication Critical patent/EA201892045A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/753—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring of polycyclic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/55—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/04—Saturated compounds having a carboxyl group bound to a three or four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

В настоящем изобретении описано соединение и способ ингибирования активности белка, связывающего жирные кислоты (FABP), включающий контактирование FABP с указанным соединением, имеющим структуру
EA201892045A 2016-03-11 2017-03-10 ПРОИЗВОДНЫЕ α-ТРУКСИЛЛОВОЙ КИСЛОТЫ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ С НИМИ EA201892045A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662307262P 2016-03-11 2016-03-11
PCT/US2017/021711 WO2017156354A1 (en) 2016-03-11 2017-03-10 α-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF

Publications (1)

Publication Number Publication Date
EA201892045A1 true EA201892045A1 (ru) 2019-04-30

Family

ID=59789897

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892045A EA201892045A1 (ru) 2016-03-11 2017-03-10 ПРОИЗВОДНЫЕ α-ТРУКСИЛЛОВОЙ КИСЛОТЫ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ С НИМИ

Country Status (12)

Country Link
US (3) US10968163B2 (ru)
EP (1) EP3452441A4 (ru)
JP (1) JP6976581B2 (ru)
KR (1) KR102365059B1 (ru)
CN (1) CN109415295B (ru)
AU (1) AU2017230790B2 (ru)
BR (1) BR112018068414B1 (ru)
CA (1) CA3017496A1 (ru)
EA (1) EA201892045A1 (ru)
MX (1) MX2018010801A (ru)
SG (2) SG10202008700VA (ru)
WO (1) WO2017156354A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2802049T3 (es) 2012-07-20 2021-01-15 Univ New York State Res Found Derivados de ácido alfa- y gamma-truxílico y composiciones farmacéuticas de los mismos
CA3017496A1 (en) 2016-03-11 2017-09-14 The Research Foundation For The State University Of New York A-truxillic acid derivatives and pharmaceutical compositions thereof
US20230017948A1 (en) 2019-11-25 2023-01-19 The Research Foundation For The State University Of New York Combination therapy using fabp5 inhibitors with taxanes for treatment of cancer
MX2023004171A (es) * 2020-10-08 2023-07-07 Univ New York State Res Found Derivados de monoéster de ácido truxílico como inhibidores selectivos de fabp5 y composiciones farmacéuticas y usos de estos.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903297A (en) 1973-11-01 1975-09-02 Upjohn Co Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs
JP2001199884A (ja) 2000-01-21 2001-07-24 Seiwa Yakuhin Kk 鎮痛作用剤
ES2189602B1 (es) 2000-10-11 2004-08-01 Universidad De Murcia Procedimiento para la inmovilizacion de un ligando sobre un soporte.
JP2002154959A (ja) * 2000-11-15 2002-05-28 Seiwa Yakuhin Kk 鎮痛抗炎症作用剤
AU2002348276A1 (en) 2001-11-16 2003-06-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
JP2011507910A (ja) * 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
US8980820B2 (en) 2009-01-19 2015-03-17 The Research Foundation For The State University Of New York Fatty acid binding proteins as drug targets for endocannabinoids
CN101838239B (zh) 2010-02-02 2012-03-21 中国科学院广州生物医药与健康研究院 一种吡唑类化合物及其组合物和应用
ES2802049T3 (es) * 2012-07-20 2021-01-15 Univ New York State Res Found Derivados de ácido alfa- y gamma-truxílico y composiciones farmacéuticas de los mismos
EP2895481B1 (en) * 2012-09-12 2019-12-11 F.Hoffmann-La Roche Ag Non-annulated thiophenylamides as inhibitors of fatty acid binding protein (fabp) 4 and/or 5
CA3017496A1 (en) 2016-03-11 2017-09-14 The Research Foundation For The State University Of New York A-truxillic acid derivatives and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
WO2017156354A1 (en) 2017-09-14
CA3017496A1 (en) 2017-09-14
US20190062261A1 (en) 2019-02-28
SG11201807365QA (en) 2018-09-27
US20240092725A1 (en) 2024-03-21
KR20180120230A (ko) 2018-11-05
EP3452441A4 (en) 2019-10-23
BR112018068414B1 (pt) 2022-08-23
US20210179535A1 (en) 2021-06-17
JP2019510086A (ja) 2019-04-11
MX2018010801A (es) 2019-02-07
CN109415295B (zh) 2022-05-17
JP6976581B2 (ja) 2021-12-08
KR102365059B1 (ko) 2022-02-18
EP3452441A1 (en) 2019-03-13
US10968163B2 (en) 2021-04-06
AU2017230790A1 (en) 2018-11-01
CN109415295A (zh) 2019-03-01
AU2017230790B2 (en) 2021-07-08
SG10202008700VA (en) 2020-10-29
BR112018068414A2 (pt) 2019-01-22
US11739047B2 (en) 2023-08-29

Similar Documents

Publication Publication Date Title
DK3873903T3 (da) Substituerede 6-azabenzimidazolforbindelser som hpk1-hæmmere
EA201890749A1 (ru) ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) И ИХ ПРИМЕНЕНИЕ
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
BR112015031073A2 (pt) inibidores bicíclicos de bromodomínio
EA201891438A1 (ru) Кислотно-аддитивные соли производных пиперазина
EA201691794A1 (ru) Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
EA201790108A1 (ru) Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента
EA201791867A1 (ru) Бициклические гетероциклы как ингибиторы fgfr4
DK3330259T3 (da) 1,3,4-oxadiazolamidderivativ-forbindelse som histondeacetylase-6-inhibitor og farmaceutisk sammensætning indeholdende denne
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
CU20180001A7 (es) Derivados de oxopiridina sustituidos y procesos para su preparación
EA201890123A1 (ru) Новые аминокислотные производные, способ их получения и фармацевтические композиции, содержащие их
EA201890124A1 (ru) Новые гидроксикислотные производные, способ их получения и фармацевтические композиции, содержащие их
EA201691134A1 (ru) Новые ингибиторы глутаминазы
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
EA201591420A1 (ru) Гетероарильные соединения и их применение
EA201591961A1 (ru) Ингибиторы акк и их применение
EA201591960A1 (ru) Ингибиторы акк и их применение
EA201692548A1 (ru) Минеральные аминокислотные комплексы активных веществ
EA201591931A1 (ru) Композиции оксабициклогептанов и оксабициклогептенов
EA201690764A1 (ru) Ингибитор грелин-o-ацилтрансферазы
EA201792021A1 (ru) Ингибитор jak
EA201890386A1 (ru) Ингибитор мутированной изоцитратдегидрогеназы idh1 r132h
EA201892045A1 (ru) ПРОИЗВОДНЫЕ α-ТРУКСИЛЛОВОЙ КИСЛОТЫ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ С НИМИ
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения